在阿尔茨海默病协会国际会议（AAIC）上，Ionis Pharmaceuticals 的合作伙伴百健（Biogen）公布了Celia二期研究数据。结果显示，在早期阿尔茨海默病患者中，候选药物Diranersen展现出具有临床意义的积极结果，并实现了Tau蛋白水平的强劲降低。
在阿尔茨海默病协会国际会议（AAIC）上，Ionis Pharmaceuticals 的合作伙伴百健（Biogen）公布了Celia二期研究数据。结果显示，在早期阿尔茨海默病患者中，候选药物Diranersen展现出具有临床意义的积极结果，并实现了Tau蛋白水平的强劲降低。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.